---
title: "JonesTrading Sticks to Its Hold Rating for Day One Biopharmaceuticals (DAWN)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281797417.md"
description: "JonesTrading analyst Soumit Roy has maintained a Hold rating on Day One Biopharmaceuticals (DAWN) with a price target of $21.50. The analyst consensus for the stock is also a Hold, with an average price target of $20.86. Roy specializes in the Healthcare sector and has an average return of -7.2% with a 32.22% success rate on his stock recommendations."
datetime: "2026-04-06T20:40:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281797417.md)
  - [en](https://longbridge.com/en/news/281797417.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281797417.md)
---

# JonesTrading Sticks to Its Hold Rating for Day One Biopharmaceuticals (DAWN)

JonesTrading analyst Soumit Roy maintained a Hold rating on Day One Biopharmaceuticals today and set a price target of $21.50.

### Easter Sale - 70% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Roy covers the Healthcare sector, focusing on stocks such as CervoMed, Enliven Therapeutics, and Oric Pharmaceuticals. According to TipRanks, Roy has an average return of \-7.2% and a 32.22% success rate on recommended stocks.

Currently, the analyst consensus on Day One Biopharmaceuticals is a Hold with an average price target of $20.86.

### Related Stocks

- [DAWN.US](https://longbridge.com/en/quote/DAWN.US.md)

## Related News & Research

- [Day One Biopharmaceuticals, Inc. $DAWN Shares Sold by NEOS Investment Management LLC](https://longbridge.com/en/news/276532690.md)
- [Wedbush Forecasts Strong Price Appreciation for Day One Biopharmaceuticals (NASDAQ:DAWN) Stock](https://longbridge.com/en/news/276898415.md)
- [How investors can navigate the healthcare sector](https://longbridge.com/en/news/293960711.md)
- [Rhythm Pharmaceuticals (RYTM) Faces A Big Undervaluation Call, Is The Upside Already Priced In?](https://longbridge.com/en/news/293893019.md)
- [Goldman Sachs Reaffirms Their Buy Rating on Amneal Pharmaceuticals (AMRX)](https://longbridge.com/en/news/293926120.md)